A major challenge in cancer genetics is to determine which low-frequency somatic mutations are drivers of tumorigenesis. Here we interrogate the genomes of 7,651 diverse human cancers and find inactivating mutations in the homeodomain transcription factor gene CUX1 (cut-like homeobox 1) in 1-5% of various tumors. Meta-analysis of CUX1 mutational status in 2,519 cases of myeloid malignancies reveals disruptive mutations associated with poor survival, highlighting the clinical significance of CUX1 loss. In parallel, we validate CUX1 as a bona fide tumor suppressor using mouse transposon-mediated insertional mutagenesis and Drosophila cancer models. We demonstrate that CUX1 deficiency activates phosphoinositide 3-kinase (PI3K) signaling through direct transcriptional downregulation of the PI3K inhibitor PIK3IP1 (phosphoinositide-3-kinase interacting protein 1), leading to increased tumor growth and susceptibility to PI3K-AKT inhibition. Thus, our complementary approaches identify CUX1 as a pan-driver of tumorigenesis and uncover a potential strategy for treating CUX1-mutant tumors.
Most sequencing studies are only sufficiently sensitive to identify commonly mutated cancer genes, and cancer drivers mutated at low frequency often escape detection. To address this issue, we used an extensive collection of 7,651 genome sequences (352 whole genomes, 7,299 exomes) derived from 28 tumor types to identify cancer driver genes characterized by loss-of-function mutations (Supplementary Table 1 ). Our strategy, which involved searching for genes showing a significant enrichment for nonsense mutations (see Online Methods), identified 54 genes (q < 0.01). These included known drivers of tumorigenesis such as CDKN2A, TP53 and PTEN, and genes not previously implicated as recurrently mutated tumor suppressors (for example, ARHGAP35, LARP4B, AMOT and MGA), providing a hitherto unseen picture of the cancer gene landscape (Fig. 1a) . Here we focused on CUX1, which showed a 3.4-fold increase in the ratio of observed to expected nonsense mutations (q = 0.0006). Across all samples, nonsense and frameshift deletion or insertion lesions accounted for 21% of mutations in CUX1, with 51% of mutations being missense, around half of which were classed as disruptive by SIFT 1 and PolyPhen-2 (ref.
2) (Fig. 1b,c and Supplementary Table 2) . Overall nonsense and frameshift mutations in CUX1 were detected in 1-5% of tumors, spanning many types, with the highest frequency occurring in endometrial cancer (Fig. 1c) .
The CUX1 transcription factor (also known as CUTL1 or CDP) contains four DNA-binding motifs-three CUT repeats and a C-terminal homeodomain 3 -and has numerous cellular functions 4, 5 . Previous studies have identified multiple CUX1 isoforms with differing transcriptional activation properties; whereas full-length CUX1 p200 acts as a transcriptional repressor, proteolytic cleavage of the N terminus generates a truncated CUX1 p110 isoform with transcriptional activation properties 6 . Additionally, a shorter pro-tumorigenic CUX1 p75 isoform found in breast tumors and certain normal tissues-for example, in the thymus-can be generated by transcriptional initiation from within intron 20 (ref. 7) (Fig. 1d) .
Most studies to date have attributed an oncogenic role for CUX1 in human cancer (Supplementary Note). However, a recent gene expression study found an ~50% reduction in CUX1 levels in 11 cases of acute myeloid leukemia (AML) characterized by complete or partial monoallelic loss of chromosome 7, where CUX1 resides, leading to the proposal that CUX1 is a haploinsufficient myeloid tumor suppressor 8 . To evaluate the role of CUX1 in myeloid cancers more comprehensively, we carried out a meta-analysis of our sequencing studies that targeted CUX1 coding exons 9 (A.R.G., E.P., H.D., J.N., P.J.C. et al., unpublished data). We found no mutations in exomes from 151 patients with myeloproliferative neoplasms ( Supplementary  Fig. 1a) . In a targeted gene screen of 111 genes in 738 patients with myelodysplasia (MDS), a clonal pre-leukemic hematopoietic condition, and related myelodysplastic/myeloproliferative neoplasms (MDS/MPN) such as chronic myelomonocytic leukemia (CMML) 9 , l e t t e r s we identified 22 CUX1 mutations including heterozygous inactivating (nonsense, frameshift and essential splice site) variants in 15 samples (2%) (Fig. 1e and Supplementary Table 3 ). An identical screen applied to 1,630 patients with AML ( Supplementary Fig. 1a ) identified 10 CUX1 mutations (nine inactivating, one missense) ( Fig. 1e and Supplementary Table 3) . CUX1 mutations did not co-occur with −7/del(7q) abnormalities, consistent with the notion that CUX1 is a haploinsufficient tumor suppressor (Supplementary Table 3) . However, one patient with CMML harbored compound heterozygous nonsense CUX1 mutations, suggesting that CUX1 can also function, though rarely, as a classical tumor suppressor, as observed in one case with myeloproliferative disease 10 . CUX1 mutations were found across most MDS subtypes, including refractory anemia-thought to represent an early stage in MDS evolution-suggesting that CUX1 mutations can arise around disease initiation (Supplementary Fig. 1b) . CUX1 mutations were relatively frequent in CMML, accounting for 7/70 (10%) cases (Supplementary Fig. 1c) . Given that the presence of −7/del(7q) lesions in myeloid malignancies is associated with poor prognosis 11 , we compared the overall survival of CUX1-truncating to −7/del(7q) cases in cohorts with myeloid disease. In MDS and MDS/MPN, both CUX1 inactivation and −7/del(7q) were associated with poorer overall survival, even after correction for age and World Health Organization (WHO) category (P = 0.03 and P = 0.0004, respectively) (Fig. 1f) . With AML, there was a tendency toward poorer survival in CUX1-truncating cases (P = 0.1), whereas −7/del(7q) was associated with a significantly worse overall outcome (P < 0.0001), after correction for age and randomized treatment (Fig. 1g) . A larger cohort of AML cases will be required to assess further the impact of CUX1 mutations, but nonetheless, our data suggest that CUX1 loss is an important independent prognostic indicator and determinant of unfavorable outcome in −7/del(7q) myeloid malignancies. Histogram showing genes with increased ratios of observed to expected nonsense mutations (Benjamini-Hochberg's false discovery rate-adjusted P value, q < 0.01). Genes are ranked according to the observed-toexpected ratio using a mutation-selection model as described 24 npg l e t t e r s
Although these genomic data strongly suggested that CUX1 functions as a tumor suppressor, we used cross-species oncogenomics approaches in mice and Drosophila to provide corroborative evidence. As we found CUX1 mutations in myeloid neoplasms, we speculated that CUX1 might be a conserved hematopoietic tumor suppressor, a notion supported by the myeloid hyperplasia phenotype of Cux1-deficient mice 12 . Previously, we have used transposon-mediated mutagenesis in mice as an unbiased forward-genetic approach to uncover cancer genes in a tissue-specific manner 13 . A screen performed in hematopoietic tissues using mice carrying Sleeping Beauty T2/Onc transposons 14, 15 , a conditional transposase (CAGGS-SB11; SB11) allele 13 , and a polyinosinic-polycytidylic acid (pIpC)-inducible pan-hematopoietic Cre driver (Mx1-Cre) 16 (Supplementary Fig. 2 ) led to T-cell lymphoblastic lymphoma (T-ALL) in >80% triple transgenic mice with a median survival of 120 days following pIpC injection (Fig. 2a) . Tumors from these mice were CD3 + ;Tdt + and showed clonal T-cell receptor rearrangements confirming a diagnosis of T-ALL (Fig. 2b,c) . Transposon insertion site analysis from 44 tumors revealed 90 genes associated with common insertion sites (CIS) (P < 0.05) (Supplementary Table 4) . Notably, 20 (45%) tumors contained sense or antisense insertions in Cux1, including six tumors with two insertions and one tumor harboring three insertions (Fig. 2d) .
Insertions were also present in 14 key genes previously associated with human T-ALL, highlighting the human relevance and sensitivity of our screen ( Supplementary Fig. 3 and Supplementary Table 5) . Although the bi-directional pattern of transposon insertions within Cux1 was typical of gene inactivation 17 , shorter, potentially oncogenic Cux1 isoforms could theoretically be produced where the transposon npg l e t t e r s lands in a 'forward' orientation as a result of transcriptional activation by the MSCV promoter. Thus, we first confirmed the presence of truncating Cux1-T2/Onc fusion transcripts in independent tumors by RT-PCR ( Fig. 2e and Supplementary Fig. 4) , and then used qRT-PCR to demonstrate a ~50% reduction in Cux1 levels in tumors with Cux1 insertions compared with tumors without such insertions ( Fig. 2f and Supplementary Fig. 5a ). Immunoblotting confirmed a reduction in all Cux1 protein isoforms (Fig. 2g) . There was no increase in the expression of Cux1 I20 , encoding oncogenic Cux1 p75 , in tumors with Cux1 insertions (Supplementary Fig. 5b ). Additionally, Cux1 insertions were present in 59-79% of cells in three tumors analyzed, suggesting that Cux1 insertions arose in a dominant tumor clone (Supplementary Fig. 6 ). Residual Cux1 expression was detectable, even in tumors with two Cux1 insertions ( Fig. 2f and Supplementary  Fig. 5a , red points; Fig. 2g, lanes 6, 7) , suggesting monoallelic or bi-clonal insertion events. Altogether, these data indicate that Cux1 insertions led to predominantly heterozygous gene inactivation akin to the nature of most human CUX1 mutations. Finally, to explore the degree of evolutionary conservation of CUX1 in tumorigenesis, we used a Drosophila cancer model. Marked cell proliferation was observed after depletion of CUX1 (cut in Drosophila) either in the proliferating eye disc in conjunction with Delta (Dl) Notch-ligand expression 18 (Fig. 2h) or alone in the lymph gland and larvae 8 ( Fig. 2i-k) , indicating intrinsic cut tumor suppressive activity. Although the exact contribution of CUX1 in human T-ALL requires further investigation (Supplementary Note), our collective data support the hypothesis that CUX1 is an evolutionarily conserved tumor suppressor.
To explore the mechanisms of tumor suppression by CUX1 we depleted CUX1 in human LOUCY T-ALL cells by RNA interference (Fig. 3a,b) and carried out transcriptome profiling to identify 99 downregulated genes and 62 upregulated genes in CUX1-knockdown cells (fold change of >1.5, P < 0.005) (Supplementary Fig. 7 and Fig. 7 ). Gene ontology analysis of dysregulated genes showed perturbation of a range of biological processes, including cell cycle control and, notably, regulatory components of the PI3K-signaling axis ( Supplementary Fig. 7 and Supplementary Table 7) .
Supplementary Table 6). Regulation of several targets was validated by qRT-PCR (Supplementary
Given the importance of PI3K signaling in cancer, we assessed the effects of CUX1 loss on the PI3K pathway and found increased phosphorylation of AKT and RPS6 in CUX1-knockdown LOUCY cells (Fig. 3c) . Stable shRNA-mediated knockdown of CUX1 in KE37 T-ALL cells also led to increased phosphorylation of AKT and its substrate GSKα/β (Fig. 3d) , as well as increased glucose uptake (Fig. 3e) . The most highly downregulated gene in our transcriptome analysis was PIK3IP1, whose protein product binds the p110 catalytic subunit of PI3K heterodimers, thereby antagonizing PI3K catalytic activity 19, 20 . Consistent with these microarray data, and qRT-PCR results (Fig. 3f) , we found reduced PIK3IP1 protein concentrations in CUX1-depleted LOUCY (Fig. 3c ) and KE37 cells (Fig. 3d) . To determine whether downregulation of PIK3IP1 was responsible for activation of PI3K-AKT signaling in this context, we confirmed that PIK3IP1 knockdown in T-ALL cells increased phospho-AKT levels (Fig. 3g,h) , and showed that enforced PIK3IP1 expression in CUX1-shRNA knockdown cells attenuated AKT activation (Fig. 3i) . Subcutaneous injection of NOD-SCID immunodeficient mice with KE37 cells transduced with shRNA vectors that target CUX1 or PIK3IP1 resulted in the formation of larger tumors with systemic spread of tumor cells, indicating that CUX1 and PIK3IP1 are tumor suppressors in vivo (Fig. 3j,k and Supplementary Fig. 8) .
Previous studies have shown that CUX1 has a binding preference for ATC(G/A)AT consensus DNA sequences on target gene promoters [21] [22] [23] . To investigate whether CUX1 regulates PIK3IP1 expression directly, we inspected the PIK3IP1 genomic locus and found two l e t t e r s putative CUX1-binding sites ~3 kb upstream of the PIK3IP1 transcriptional start site (Fig. 4a) . By using a ~4.3-kb PIK3IP1 genomic fragment encompassing these two putative CUX1-binding sites in luciferase reporter assays, we found that exogenous CUX1 p110 could transactivate PIK3IP1-luciferase expression ~10-fold (Fig. 4b) . Mutation of both putative CUX1-binding sites within the reporter construct, or expression of a homeodomain-deletion CUX1 p110 mutant, led to a significant (P < 0.001) reduction of luciferase activity (Fig. 4b) ; the residual luciferase activity observed using these mutants was possibly attributable to additional, unidentified binding sites in the reporter. Subsequently, ChIP assays in LOUCY cells demonstrated direct binding of CUX1 to the PIK3IP1 promoter in vivo (Fig. 4c) . Collectively, these data show that CUX1 modulates PI3K signaling through direct transcriptional regulation of PIK3IP1 expression ( Supplementary  Fig. 9 ). As most human CUX1 mutations seem to be heterozygous, we next investigated whether expression of CUX1 at levels attributable to gene haploinsufficiency was sufficient to affect both PIK3IP1 expression and PI3K signaling. Consistently, mouse transposon tumors expressing ~50% Cux1 levels showed decreased expression of Pik3ip1 associated with higher phospho-Akt levels (Fig. 2g) , and human SUP-T1 T-ALL cells, which harbor a heterozygous CUX1-truncating mutation, also showed similar reciprocal alterations (Supplementary Fig. 10 ).
Given that PI3K signaling is hyperactivated in CUX1-deficient cells, we investigated the therapeutic merits of PI3K-AKT pathway inhibition. To minimize other genetic factors confounding responses, we evaluated the viability of KE37 cell lines, which were co-isogenic apart from carrying control or CUX1-shRNA knockdown vectors, exposed to a pan-AKT inhibitor (MK2206), or a dual PI3K/mTOR inhibitor (NVP-BEZ235). We also compared the responses to both compounds of H2803 mesothelioma cells, which harbor a focal homozygous deletion of CUX1 (Supplementary Fig. 11) , with those of a panel of wildtype CUX1 mesothelioma cell lines. Notably, both CUX1-deficient cell lines showed increased sensitivity to drug treatment compared with controls, suggesting increased dependency on PI3K-AKT-mTOR signaling (Fig. 4d,e and Supplementary Fig. 12 ). Consistently, SUP-T1 cells were also more sensitive to MK2206 treatment compared with cells with higher expression of CUX1 (Supplementary Fig. 10 ). Thus our data support an important role for CUX1 deficiency in PI3K signaling, but as CUX1 functions in multiple biological processes, other CUX1-mediated tumor suppressive mechanisms may also operate. Nonetheless, the susceptibility of CUX1-mutant cells to PI3K-AKTmTOR pathway inhibition provides a potential therapeutic avenue. Finally, in addition to identifying CUX1 as a pan-driver of cancer in this study, our approach also highlighted additional tumor suppressor candidates that warrant investigation in the future (Supplementary Note and Supplementary Table 8) .
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npg oNLINe MeTHods
Collection of human cancer data sets. We curated freely available somatic mutations from three sources: the data portal of The Cancer Genome Atlas (TCGA), the data portal of the International Cancer Genome Consortium (ICGC) and other published studies . For all cancers used as part of our analysis, normal DNA had also been sequenced to establish the somatic origin of variants. Further, extensive filtering was performed to remove any residual germline mutations and technology-specific sequencing artifacts before analyzing the data. This involved filtering for germline mutations from dbSNP 62 , the 1000 Genomes Project 63 and NHLBI GO Exome Sequencing Project 64 . Optimized minor allele frequency cut-offs were applied in order to avoid removing known driver mutations, and variants were only excluded if they exactly matched a germline variant call. Technology-specific sequencing artifacts were filtered using a panel of matched BAM files (between 120 and 500 BAMs per technology) representing the sequence of unmatched germline controls. Any candidate somatic mutation present in at least three well-mapping reads in at least two normal BAM files was discarded. Curated somatic mutation sets were lifted between genomes using UCSC's liftover tool. Ambiguously mapped calls were discarded.
Statistical analysis and human cancer data sets. To identify genes with a rate of missense, nonsense and splice site mutations higher than expected by chance, we used an adaptation of a previously described method 24 . Briefly, the rate of mutations is modeled as a Poisson process, with a rate given by a product of the mutation rate and the impact of selection. In particular, we use 12 parameters to describe the different rates of the 12 possible single-nucleotide substitutions, 2 parameters to account for the CpG context-dependent effect on C>T transitions in each strand, and 3 selection parameters to measure the observed-over-expected ratio of missense (wMIS), nonsense (wNON) and essential splice site (wSPL) mutations. For example, the expected number of A>C missense mutations is modeled as λ mis,AtoC = (t)*(AtoC)*(wMIS)* (L mis,AtoC ). "AtoC" refers to the relative rate of A>C transversions. "t" refers to the local mutation rate or the local density of mutations, which helps to control for gene-to-gene variations in coverage or in the background mutation rate. The inclusion of "t" makes one of the substitution rates unnecessary and so arbitrarily we fix GtoT = 1. "wMIS" represents the rate of missense mutation relative to synonymous mutations, and can be interpreted as the observed-over-expected ratio of missense mutations. "L mis,AtoC " represents the number of sites that can suffer a missense A>C mutation in the gene sequence (thus accounting for the length and the sequence of the gene). The likelihood of observing a given number of missense A>C mutations in a particular gene (n mis,AtoC ), given the expected rate (λ mis,AtoC ), is calculated as follows: 
The likelihood of the entire model is the product of the individual likelihoods of each of the 14 mutation types:
This allows us to quantify separately the strength of selection at missense, nonsense and essential splice site mutations, avoiding the confounding effects of gene length, sequence composition and different rates of each substitution type. To obtain accurate estimates of the relative rates of each substitution type, the 14 rate parameters were estimated from the entire collection of mutations. These rates were then assumed constant and maximum-likelihood estimates for "t," "wMIS," "wNON" and "wSPLICE" were obtained for each gene. Likelihood Ratio Tests were then used to test deviations from neutrality (wMIS = 1, wNON = 1 or wSPL = 1). P values were adjusted for multiple testing using Benjamini-Hochberg False Discovery Rate. In Figure 1 only genes with wNON >1 and q value <0.01 are shown, representing a set of candidate tumor suppressor genes.
Mouse strains and common insertion site (CIS) analysis. T2/Onc, CAGGS-SB11
and Mx1-Cre mouse strains were kindly provided by L. Collier (University of Wisconsin-Madison), A. Uren (Imperial College London) and P. Liu (Wellcome Trust Sanger Institute), respectively. The mice were on a predominantly C57BL/6J background. Mice were housed according to Home Office regulations (United Kingdom) and all procedures were performed with Home Office approval. At ~6 weeks of age, 51 mice were randomly assigned to study groups and injected intraperitoneally with either six doses of 250 µg pIpC (GE Healthcare) over two weeks to induce Cre recombinase expression (23 males, 21 females) or PBS as controls (4 males, 3 females). Allocation to study groups was blinded. Genomic DNA was isolated from thymic tumors, bone marrow and spleens from killed mice using a Puregene Core Kit A (Qiagen). To detect transposon mobilization, PCR was performed on genomic DNA using T2/onc-Excision-F and T2/onc-Excision-R primers. Oligonucleotides used in this study are listed in Supplementary Table 9 . Splinkerette PCR and CIS analysis were performed as described previously 13 . Chromosome 1, harboring the transposon concatamer, was excluded from CIS analysis to account for local hopping.
RT-PCR detection of Cux1-T2/Onc and Pten-T2/Onc fusion mRNA in mouse transposon tumors. RNA was prepared from frozen suspensions of transposon tumors using an RNeasy Mini kit (Qiagen) and reverse transcribed into cDNA using Superscript III (Invitrogen) primed with random hexamers. PCR was performed using primer pairs mCuxEX2F/UnivRevT2onc1, mCux1ex8/UnivRevT2onc1 or mCuxEX19F/carpSA1 to detect Cux1-T2/ Onc fusion transcripts. Primers mPtenex2 and CarpSA1 were used to detect Pten-T2/Onc fusion mRNA. PCR products were cloned using a TOPO TA cloning kit (Invitrogen) and individual clones were sequenced.
Mouse pathology. Air-dried blood smears were stained with MGG (Sigma).
Mouse tissues were fixed in formalin and embedded in paraffin. Blocks were cut into 5 µm sections and stained with hematoxylin/eosin. For immunohistochemistry, antigen retrieval was performed by microwaving sections in Following TBST washes, signal detection was accomplished using an Elite Vectastain ABC kit and DAB (Vector Laboratories). Sections were counterstained with hematoxylin before dehydration and mounting. Slide images were captured using a Nanozoomer digital slide scanner (Hamamatsu).
TCRb gene rearrangement. PCR was performed on genomic tumor DNA using primers DB2.1 and JB2.7. and processed for immunofluorescence as described previously 67 . Primary antibodies were mouse anti-Lozenge (1:20; DSHB/Hybridoma Bank), goat anti-GFP (8:300; Abcam, ab6673). Secondary antibodies were FITC antigoat (1:200) and Cy3 anti-mouse (1:100) from Jackson ImmunoResearch. Samples were mounted using Vectashield mounting medium containing DAPI and imaged using a Nikon D-ECLIPSE C1. Pupae and adult flies from the same genotypes were also scored for the presence of melanotic tumors (detectable as pigmented masses present beneath the cuticle of living specimens).
Gene expression profiling. RNA was extracted from siRNA-treated cells from three independent knockdown experiments using an RNeasy Mini Kit 
, ,
Pois l ∈ ∏ npg (Qiagen) and processed for transcriptome profiling using a HumanHT-12 v4 Expression BeadChip Kit (Illumina). Raw probe data were transformed into log-scale expression values using variance stabilization transformation 68 and quantile normalized. Differentially expressed genes were identified by fitting an individual linear model for each gene across different sample groups 69 . GO analysis was performed using DAVID 70 .
Quantitative PCR. RNA was extracted from cell lines or mouse tumors using an RNeasy Mini kit (Qiagen). Contaminating DNA was digested using TURBO DNase (Ambion). Total RNA was reversed transcribed using RNA to cDNA EcoDry Premix (Clontech). Quantitative reverse transcriptase PCR (qRT-PCR) was carried out using SYBR-Green PCR Master Mix (Applied Biosystems) on a 7900HT Real-Time PCR machine (Applied Biosystems). Gene expression was normalized to GAPDH expression. A ∆∆Ct loss of copy number approach was used to determine the burden of Cux1 transposon insertions within a given tumor sample. Quantitative PCR was performed on wild-type and tumor genomic DNA samples using primers flanking individual transposon insertion sites. The Sh2b2 gene, amplified with mSh2b2EX2QF and mSh2b2EX2QR primers, was used as a reference. The insertion-specific primers used are shown in Supplementary Table 9 .
Semi-quantitative RT-PCR. Semi-quantitative RT-PCR was performed to detect Cux1 I20 mRNA species in mouse tumors using primers as described 7 .
Gapdh expression was used as a control.
Immunoblotting. Cells were washed in PBS before resuspension in Cellytic (Sigma) supplemented with protease/phosphatase inhibitor cocktail (Cell Signaling). Cells were lysed using a TissueLyser LT (Qiagen). Samples were centrifuged at 13,000 rpm for 10 min to pellet insoluble debris. Protein concentrations were determined by Bradford assay. Equal amounts of protein were resolved on 4-12% Bis-Tris SDS-PAGE gels (Novex) and transferred to nitrocellulose membranes (GE Healthcare). Immunoblotting was performed according to standard techniques using primary antibodies including anti-CUX1 ( Plasmids, shRNAs and siRNA. Oligonucleotides for shRNA knockdowns were cloned into PLKO.pig. For siRNA experiments, LOUCY cells were resuspended in Opti-MEM (Gibco) and electroporated in 4 mm cuvettes (300 V, 1,000 µF; Genepulser XCell, Bio-Rad) using Stealth siRNAs (Ambion) against CUX1, PIK3IP1 or negative control duplexes. Cells were rested for 15 min following electroporation before dilution into normal growth media. Cells were processed for downstream analysis 48-72 h later. For PIK3IP1 expression, the PIK3IP1 coding sequence was amplified and myc-tagged by PCR using PIKRIf and PIKmycBglR using IMAGE clone 4180134 as template. The PCR product was digested with EcoRI and BglII before cloning into MSCV-neo (Clontech) digested with the same enzymes. All vectors were verified by sequencing.
Cell culture. LOUCY and KE37 human T-ALL cells originated from DSMZ and were grown at 37 °C and 5% CO 2 in RPMI supplemented with 20% or 10% FBS, respectively, glutamine and antibiotics. 293T cells, which originated from ATCC, and Phoenix cells (from Clontech) were grown in DMEM with 10% FBS, glutamine and antibiotics. The identity of cell lines was confirmed before use, and all cell lines were mycoplasma tested before entering the laboratory. Cell lines injected into mice received a complete MAP/pathogen test.
Virus production and infection. For lentivirus production, HEK293T cells were seeded onto 15 cm plates and incubated overnight before calcium phosphatemediated transfection with pLKO.pig shRNA vectors, pMDLg/prre, pRSVRev and pMD2-VSV-G. After 16 h, 5 mM sodium butyrate (Sigma) was added to maximize virus production. For retrovirus production, 5 × 10 6 PhoenixAmpho cells were incubated overnight on 10 cm plates and transfected with MSCV expression vectors using calcium phosphate precipitation. Viral supernatants were harvested 48 h post transfection and passed through 0.45 µm filters before infection of target cells or storage at −80 °C. Target cells were infected by incubation for 4-8 h with viral supernatant in the presence of 4 µg/ml polybrene. Cells transduced with PLKO.pig and MSCV vectors were selected with 6 µg/ml puromycin and 1 mg/ml G418, respectively.
Glucose uptake assay. Cells were washed in PBS and resuspended in glucosefree RPMI media (Gibco). 2.5 × 10 4 cells in 100 µl were dispensed in triplicate into 96-well plates. After 30 min, 100 µl glucose-free RPMI supplemented with 20% FBS and 2-NBD glucose (2-, deoxy-2-[(7-,nitro-2,1,3-benzoxadiazol-4-yl)amino]-d-glucose) was added to the cells. Glucose uptake was determined by fluorescence readings after 15 min according to the Glucose Uptake Kit (Cayman) protocol.
Drug treatment assays. 1 × 10 4 KE37 cells transduced with shRNA vectors were dispensed into 96 well plates in triplicate. Decreasing doses of MK2206 or NVP-BEZ235 were added to achieve a final dose spectrum from 10 µM to 0 µM. Cells were incubated for 48 h before assessment of cell viability using CellTiter-Blue reagent (Promega). Dose-response curves were generated using Prism 5 software (GraphPad). For NVP-BEZ235 and MK2206 dose response curves on mesothelioma cell lines, cell viability was assessed 72 h after drug treatment using a previously described protocol 71 .
Tumor xenograft assay. 3 × 10 6 cells in 100 µl of PBS were injected subcutaneously into the left flank of NOD-SCID mice (Jackson Laboratory). Mice were monitored daily for tumor development and the size of each tumor measured using calipers. Tumor volume = 1/2 (length × width 2 ). Mice were killed after 3 weeks and necropsies were performed. Mice were ~6 weeks old at the time of injection and were randomly assigned to each study group. Allocation to study groups was blinded.
PIK3IP1 promoter luciferase assay. To create PIK3IP1 promoter luciferase vectors, the genomic region upstream of the PIK3IP1 transcriptional start site was amplified by PCR using PIKpromSacF and PIKpromXhoR. The PCR product was digested with SacI and XhoI before cloning into pGL4.10[luc2] (Promega) digested with the same enzymes, creating pGL4.10-PIK3IP1prom WT . The 2 putative CUX1-binding sites were mutated in pGL4.10-PIK3IP1prom WT by 2 rounds of site-directed mutagenesis using PIKmut1F and PIKmut1R followed by PIKmut2F and PIKmut2R, leading to pGL4.10-PIK3IP1prom MUT . 293T cells were seeded into 24 well plates the evening before transfection. Cells were transfected with empty vector (pXJ42), CUX1 p110 (pXJ myc-CUX1 p110 -HA) or CUX1 p110 ∆HD (pXJ myc-CUX1 p110 ∆HD-HA) expression vectors along with pGL4.10-PIK3IP1prom WT or pGL4.10-PIK3IP1prom MUT and control Renilla luciferase expression vector (pGL4.75[hRluc/CMV]; Promega) using Lipofectamine 2000 (Invitrogen) according to manufacturer's instructions. Luciferase activity was assessed 24 h later using the Dual-Luciferase Reporter Assay System (Promega). Transfections were performed in triplicate on three separate occasions. Luciferase signals were normalized to Renilla and empty vector signals. The CUX1 homeodomain truncated mutant (CUX1 p110 ∆HD) was generated by PCR using CUXmyc110f and CUXdHDHAr on pXJ myc-CUX1 p110 -HA. The PCR product was cloned into pXJ42. Vectors were confirmed by sequencing.
Chromatin immunoprecipitation (ChIP).
ChIP was performed on LOUCY cells using a Magna ChIP A/G Chromatin Immunoprecipitation Kit (Millipore) with minor modifications. 5 × 10 7 formaldehyde-fixed cells were treated with 0.125 M glycine before resuspension in 1 ml lysis buffer (5 mM Tris-HCl pH 8.0, 85 mM KCl, 1% NP40 and protease inhibitors [Roche]). After 10 min on ice, the nuclei were pelleted and resuspended in 0.5 ml nuclear lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 0.3% SDS and protease inhibitors [Roche]) before 20 cycles of 30 s on/off sonication using a Bioruptor Plus device (Diagenode). Insoluble material was removed by centrifugation. An aliquot of chromatin was used to determine satisfactory sonication and DNA concentration after cross-link reversal. 100 µg chromatin was diluted in dilution buffer npg
